Medical/Pharmaceuticals
Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases
SUZHOU, China and HONG KONG, Sept. 14, 2023 /PRNewswire/ -- Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership ...
2023-09-14 23:00
1987
Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
REYKJAVIK, Iceland, Sept. 14, 2023 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system and TheCopenhagen University, publish a study today in the journal Cell titled "Complex effects of sequence variants on lipid level...
2023-09-14 23:00
2372
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing ...
2023-09-14 20:00
1566
Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies
SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to...
2023-09-14 20:00
1980
Fujitsu and Baptist Health South Florida transform operating room scheduling with newly launched solution to boost utilization rates and the financial health of the surgical discipline
Recent trials with the solution delivered 37% improvement in available
prime-time minutes over a three-month period
TOKYO, Sept. 14, 2023 /PRNewswire/ -- Fujitsu today announced the launch of
an innovative solution to its Uvance Healthy Living
2023-09-14 18:03
1386
Foundry Mixer Healthcare, Indonesian Minister of Health Budi G. Sadikin: "Together We Leapfrog Indonesia's Healthcare Transformation"
Indonesian Minister of Health, Budi Gunadi Sadikin, emphasized that investing in the Health Technology and Biotechnology sector serves not only business prospects but also strengthens Indonesia's health resilience and adds value to healthcare. JAKARTA, Indonesia, Sept. 14, 2023 /PRNewswire/ -- F...
2023-09-14 17:47
1746
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...
2023-09-14 17:07
1626
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...
2023-09-14 16:54
1570
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...
2023-09-14 16:00
1511
Neoss® Group launches NeoTell™ a new device to measure implant stability.
ZÜRICH, Sept. 14, 2023 /PRNewswire/ -- Earlier this year, Neoss Group, a pioneer in dental implant solutions, announced a partnership with Osstell AB, a global leader in implant stability measurement and osseointegration progress monitoring. Today, we proudly introduce the first fruit of this col...
2023-09-14 16:00
1696
Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan
SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...
2023-09-14 10:00
2641
Avasa raises $1.55M in oversubscribed funding round with innovative implantable devices
MIAMI and AUCKLAND, New Zealand, Sept. 14, 2023 /PRNewswire/ -- Avasa, a medical device pioneer advancing surgical techniques for improved patient outcomes, announces the successful completion of its recent funding, raising an impressive$1.55 million in capital investment. The influx of new inves...
2023-09-14 04:50
2036
AWAK TECHNOLOGIES RAISES US$20+ MILLION, READYING ITS WEARABLE DIALYSIS DEVICE FOR US-BASED PIVOTAL TRIAL
* AWAK closes one of the largest MedTech fundraise in 2023 in Southeast Asia * The Series B round was co-led by new investor Lion X Ventures and long-term investor Vickers Venture Partners, along with other new and existing investors * AWAK's ultra-portable peritoneal dialysis system enables ...
2023-09-13 21:27
2584
S-Patch Ex, Wearable ECG Patch, Cleared by US FDA
* Lightest weighing ECG patch in the market designed for comfort and ease of use * Embedded with Samsung's Next-Generation bio-processor proven to capture world's most accurate ECG waveforms SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- Wellysis, a spin-off company from Samsung SDS, has ...
2023-09-13 21:00
1979
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
1998
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...
2023-09-13 19:09
1553
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...
2023-09-13 15:58
1732
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...
2023-09-13 14:24
1522
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. - 54.8% of painful lipomas showed complete clearance or dimension reduction of more th...
2023-09-13 13:42
1440
AIRS Medical Inc. receives MDSAP Certification, Paving the Way for Global Expansion
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- AIRS Medical Inc., an AI-powered healthcare solution provider headquartered in Korea announces the attainment of MDSAP (Medical Device Single Audit Program) certification. This milestone achievement underscores AIRS Medical's commitment to qualit...
2023-09-13 12:44
1462
Week's Top Stories
Most Reposted
Star-Studded Sponsor Line-up Takes Centre Court at the Singapore Tennis Open 2025
[Picked up by 293 media titles]
2025-01-28 10:49
Sushui Tech to Launch New DMFC Products at Smart Energy Week, Tokyo 2025
[Picked up by 260 media titles]
2025-01-28 09:53
China's view of international order reflected in stories of two "apples"
[Picked up by 248 media titles]
2025-01-25 15:27Toshiba TV AI Engine Blasts Home Entertainment into New Dimensions
[Picked up by 247 media titles]
2025-01-28 09:00SURVEY REVEALS AUSTRALIANS STILL HOLIDAY MORE AT HOME
[Picked up by 230 media titles]
2025-01-29 07:38Most Read
BRI UMKM EXPO(RT) 2025 Returns: Showcasing Local Products to the World
2025-01-25 15:38
9019
U Power Announces Pricing of $5.0 Million Registered Direct Offering
2025-01-24 22:18
5842
Industrial legacy boosts tourism development in Shenyang
2025-01-24 22:18
5512